《薛雪医案》辨治胃肠疾病的文献挖掘与生物信息学分析  

Literature mining and bioinformatics analysis of Xue Xue’s Medical Cases for differentiation and treatment of gastrointestinal diseases

作　　者：苏海洋 张洋[2] 屠燕捷[3] 杨爱东[1,4] SU Haiyang;ZHANG Yang;TU Yanjie;YANG Aidong(Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Science and Technology Information Center,Shanghai Univerisity of Traditional Chinese Medicine,Shanghai 201203,China;Basic Medical College,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Center for Traditional Chinese Medicine and Epidemic Disease,Shanghai Institute of Infectious Disease and Biosecurity,Shanghai 200032,China)

机构地区：[1]上海中医药大学,上海201203 [2]上海中医药大学科技信息中心,上海201203 [3]上海中医药大学基础医学院,上海201203 [4]上海市重大传染病和生物安全研究院中医药疫病研究中心,上海200032

出　　处：《上海中医药大学学报》2023年第1期75-84,共10页Academic Journal of Shanghai University of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81904072);上海市市级科技重大专项(ZD2021CY001);上海中医药大学杏林传承人才项目(A1-U21-205-02);上海中医药大学基础医学院跋涉攀登传承计划(A1-GY20-101-0101)。

摘　　要：目的:基于中医传承辅助平台及网络药理学分析《薛雪医案》中辨治胃肠疾病的遣方用药特点及内在机制,为临床以湿热类胃肠病为代表的消化系统疾病中医诊治提供参考。方法:筛选《薛雪医案》中辨治胃肠疾病相关医案,数据标准化处理后录入中医传承辅助平台分析药物频次、组方规律等,获得核心药物组合。对核心药物组合进行蛋白质相互作用(PPI)分析、基因本体(GO)及京都基因与基因组百科全书(KEGG)富集分析,探讨核心药物组合治疗胃肠疾病的作用机制。结果:①共纳入《薛雪医案》中辨治胃肠疾病医案191则,涉及中药219味。综合药物频次、组方规律及新方分析确定厚朴、草果、人参、茯苓、陈皮、大腹皮、白术、广藿香为核心药物组合。②PPI分析显示,度值较高的蛋白包括蛋白激酶B α(Akt1)、肿瘤坏死因子(TNF)、肿瘤蛋白p53(TP53)、血管内皮生长因子A(VEGFA)、原癌基因酪氨酸蛋白激酶Src(Src)、热休克蛋白90α家族A类成员1(HSP90AA1)等,涉及磷脂酰肌醇-3-激酶/蛋白激酶B(PI3K/Akt)信号通路、缺氧诱导因子-1(HIF-1)信号通路、VEGF信号通路、癌症通路等。结论:从《薛雪医案》中分析并总结出薛氏辨治胃肠疾病核心药物组合,其具有苦燥芳化、健脾理气之功,通过多成分、多靶点、多通路发挥抗炎、抗肿瘤、抗氧化、抑菌等作用。Objective: To analyze the characteristics and internal mechanism of Xue Shengbai’s prescriptions for the differentiation and treatment of gastrointestinal diseases in Xue Xue’s Medical Cases based on the traditional Chinese medicine inheritance auxiliary platform(TCMIAP) and network pharmacology, thus providing reference for traditional Chinese medicine diagnosis and treatment of digestive system diseases represented by damp-heat gastrointestinal diseases. Methods: Medical cases related to differentiation and treatment of gastrointestinal diseases in Xue Xue’s Medical Cases were screened, and these data were standardized and entered into TCMIAP to analyze the drug frequency, prescription rules, etc. The core drug combination was obtained and analyzed by protein-protein interaction(PPI) analysis, Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) enrichment analysis, to explore its mechanism in the treatment of gastrointestinal diseases. Results:① A total of 191 medical cases of differentiation and treatment of gastrointestinal diseases in Xue Xue’s Medical Cases were included, involving 219 traditional Chinese medicines. According to the drug frequency, prescription rules and new prescription analysis, the core drug combination was confirmed as follow: Magnoliae Officinalis Cortex, Tsaoko Fructus, Ginseng Radix Et Rhizoma, Poria, Citri Reticulatae Pericarpium, Arecae Pericarpium, Atractylodis Macrocephalae Rhizoma, Pogostemonis Herba.②PPI analysis showed that proteins with high degree values included protein kinase Bα(Akt1), tumor necrosis factor(TNF), tumor protein p53(TP53), vascular endothelial growth factor A(VEGFA), proto-oncogene tyrosine-protein kinase Src(Src), heat shock protein 90 α family class A member 1(HSP90AA1), etc. And pathways such as phosphatidylinositol 3-kinase/protein kinase B(PI3K/Akt) signaling pathway, hypoxia inducible factor-1(HIF-1) signaling pathway, VEGF signaling pathway, cancer pathway were involved. Conclusion: Based on the analysis and summary of Xu

关 键 词：薛生白 胃肠疾病 中医传承辅助平台 网络药理学 

分 类 号：R259[医药卫生—中西医结合] Q811.4[医药卫生—中医内科学]